SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Spero Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.12+0.02 (+1.82%)

Close on Oct 19, 2026

Market cap: $64.92M
P/E (TTM): 28.0
Dividend yield: –

Spero Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	67	48	104	54	18	9.33	18	3.97	1.98	0.34	–
Research & Development	38	97	51	48	65	67	66	34	33	26	11
General & Administrative	21	24	26	36	42	21	16	13	11	7.22	2.20
Operating Expenses	60	121	82	96	106	88	81	47	44	34	13
Operating Income	6.31	-73	21	-42	-88	-79	-63	-43	-42	-33	-13
Interest & Investment Income	2.51	4.74	3.94	1.11	0.35	0.40	1.33	1.10	–	–	–
Other Non-Operating Income	2.52	4.80	3.92	-4.22	-1.79	0.83	2.29	1.14	1.84	0.58	0.17
Merger & Restructuring Charges	0.26	0.88	0	12	0	–	–	–	–	–	–
Asset Impairment Charges	0.59	0	5.31	0.64	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.18	-0.25	–	–	–
Pretax Income	8.83	-69	25	-46	-90	-78	-61	-42	-40	-33	-13
Income Tax Expense	0.26	0	2.60	0	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	8.57	-69	23	-46	-90	-78	-61	-42	-40	-33	-13
Minority Interest in Earnings	–	–	–	–	–	–	–	–	-1.14	-7.15	-3.00
Net Income	8.57	-69	23	–	-90	-78	-61	-42	-39	-25	-10
Preferred Dividends	–	–	–	–	0	0.55	–	–	–	–	–
Net Income to Common	–	–	–	46	-90	-79	-61	-42	-46	-30	-13
EPS (Basic)(per share)	0.15	-1.27	0.43	-1.23	-2.91	-3.52	-3.35	-2.60	-17.82	-95.87	-53.11
EPS (Diluted)(per share)	0.15	-1.27	0.43	-1.23	-2.91	-3.52	-3.35	-2.60	-17.82	-95.87	-53.11
Shares Outstanding (Basic, Weighted)(shares)	56	54	53	38	31	22	18	16	2.59	0.31	0.25
Shares Outstanding (Diluted, Weighted)(shares)	59	54	53	38	31	22	18	16	2.59	0.31	0.25
EBITDA	6.31	-73	22	-41	-87	-78	-62	-42	-41	-33	-13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 12.8%
Net margin: 15.7%
Return on equity, FY2025: 16.3%

Financial strength

Current ratio: 6.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 602.4%

Valuation

P/E ratio: 28.0
Price to sales: 1.38
Price to book: 1.47
Dividend yield: –